Soligenix, Inc. (NASDAQ: SNGX ) shares are trending on Wednesday.
Soligenix made this announcement on Tuesday addressing an urgent outbreak declared a Public Health Emergency of International Concern.
Critical Vaccine Gap Drives Catalyst
No approved vaccines exist for Bundibugyo virus, Sudan virus, or Marburg virus, creating immediate demand for rapid vaccine deployment.
Christopher J. Schaber, President and Chief Executive Officer of Soligenix, said, “Our ThermoVax® platform has successfully thermostabilized vaccines for ricin toxin, filoviruses such as Ebola, Sudan and Marburg, and for COVID. The ability to induce rapid broad immune coverage makes protein subunit vaccines competitive with other technologies requiring stringent cold-chain storage.”
According to Dr. Axel Lehrer, Professor at the University of Hawaiʻi at Mānoa who collaborated with Soligenix on vaccine development, the filovirus vaccines demonstrated 100% protection in non-human primates and remain thermostable for at least two years at 40°C (104°F) for storage and distribution in endemic African regions and national stockpiles.
What You Should Know
Soligenix also holds Food and Drug Administration Orphan Drug Designations for Sudan and Marburg orthoeoboviruses, providing seven-year market exclusivity, federal grants for clinical trials, and waiver of FDA user fees upon Biologics License Application submission.
Trading Metrics, Technical Analysis
Soligenix has a market capitalization of $7.61 million. The stock has traded between a 52-week high of $6.23 and a 52-week low of $0.28.
The stock has a Relative Strength Index (RSI) of 45.36.
Over the past 12 months, SNGX has dropped 73.14%.
The small-cap stock is currently trading near its 52-week low.
Price Action: According to Benzinga Pro data, the stock of the New Jersey-based biopharmaceutical company closed the regular session at $0.51, up 31.50%.
Benzinga's Edge Stock Rankings indicate SNGX stock has a negative price trend across all time frames.
Image via Shutterstock/ Motortion Films
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Market News and Data brought to you by Benzinga APIs© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here .
Posted In: Biotech Equities News Health Care Movers & Shakers FDA Global After-Hours Center Markets General benznews Why is it moving? World Health Organization